FGF Signaling in Parkinson's Disease

FGF Signaling in Parkinson's Disease

Overview

Fibroblast Growth Factor (FGF) signaling encompasses a family of growth factors and receptors critical for neuronal development, survival, and function. The FGF family has emerged as an important modulator in Parkinson's disease (PD), with particular relevance to dopaminergic neuron maintenance and neuroprotection[@fgf_evolution]. The recognition that neurotrophic factor signaling is deficient in PD has prompted extensive investigation of FGF pathways as potential therapeutic targets for disease modification. Unlike dopamine replacement therapies that address symptoms without affecting disease progression, FGF-based approaches aim to support the survival and function of remaining dopaminergic neurons, potentially slowing or halting neurodegeneration. The pleiotropic effects of FGF signaling on neuronal survival, neuroinflammation, and protein homeostasis make this pathway particularly attractive for the multi-target intervention likely required for effective disease modification in PD.

Historical Context

Discovery of FGF Neuroprotective Effects

FGF Signaling in Parkinson's Disease

Overview

Fibroblast Growth Factor (FGF) signaling encompasses a family of growth factors and receptors critical for neuronal development, survival, and function. The FGF family has emerged as an important modulator in Parkinson's disease (PD), with particular relevance to dopaminergic neuron maintenance and neuroprotection[@fgf_evolution]. The recognition that neurotrophic factor signaling is deficient in PD has prompted extensive investigation of FGF pathways as potential therapeutic targets for disease modification. Unlike dopamine replacement therapies that address symptoms without affecting disease progression, FGF-based approaches aim to support the survival and function of remaining dopaminergic neurons, potentially slowing or halting neurodegeneration. The pleiotropic effects of FGF signaling on neuronal survival, neuroinflammation, and protein homeostasis make this pathway particularly attractive for the multi-target intervention likely required for effective disease modification in PD.

Historical Context

Discovery of FGF Neuroprotective Effects

The initial observations linking FGF to dopaminergic neuron survival emerged from developmental neurobiology studies in the 1980s and 1990s, which demonstrated that FGF2 (basic fibroblast growth factor) could support the survival and differentiation of dopaminergic neurons in vitro and in vivo. Subsequent experiments in rodent models of PD showed that FGF2 administration could protect dopaminergic neurons from MPTP toxicity, establishing the proof-of-concept for FGF-based neuroprotection in PD[@fgf_neuroprotection]. These pioneering studies revealed that FGF2 not only promoted dopaminergic neuron survival during development but also maintained neuroprotective effects in the adult brain, suggesting therapeutic potential across disease stages.

Evolution of FGF Research in PD

The field has evolved from initial demonstrations of FGF neuroprotection to more sophisticated approaches targeting specific FGF ligands and receptors. FGF20 emerged as a particularly promising candidate based on its expression pattern in the substantia nigra and genetic association studies suggesting a role in PD risk[@fgf20_pd]. The observation that FGF20 promoter polymorphisms were associated with increased PD risk in some populations provided genetic validation for targeting this specific FGF ligand in PD therapeutics. More recent research has focused on understanding the downstream signaling mechanisms mediating FGF neuroprotection and developing delivery strategies that can effectively target the central nervous system.

FGF Family and Receptors

FGF Ligands

The FGF family consists of 22 known ligands in humans, divided into canonical and non-canonical subgroups[@fgf_evolution]:

Canonical FGFs (require heparin sulfate):

• FGF1 (aFGF): Widespread expression
• FGF2 (bFGF): Neuronal survival
• FGF4, FGF5, FGF8, FGF9: Development
• FGF16, FGF17, FGF18: Various tissues

FGF Receptors (FGFRs)

FGFRs are transmembrane tyrosine kinases:

FGFR isoforms:

• FGFR1: High in neurons
• FGFR2: Expressed in glia
• FGFR3: Lower CNS expression
• FGFR4: Limited CNS expression

FGF in the Healthy Brain

Expression in Dopaminergic Systems

FGF signaling is essential for dopaminergic neuron development and maintenance[@fgf_dopamine_dev]:

• FGF2: Promotes dopaminergic neuron differentiation and survival
• FGF8: Critical for mesencephalon development
• FGF20: Specifically supports dopaminergic neurons

Neurotrophic Functions

FGF signaling promotes:

FGF Signaling in PD

Altered Expression

Studies show FGF dysregulation in PD:

| Factor | Finding | Implications |
|--------|---------|--------------|
| FGF2 | Elevated in PD CSF | Compensatory response |
| FGF2 | Reduced in SNc | Loss of neuroprotection |
| FGFR1 | Altered in PD brains | Receptor dysfunction |
| FGF20 | Genetic associations | Risk modification |

The elevation of FGF2 in cerebrospinal fluid (CSF) of PD patients appears to represent a compensatory response to ongoing neurodegeneration, with surviving dopaminergic neurons upregulating neurotrophic factor production in an attempt to protect themselves. However, this compensatory mechanism is ultimately insufficient to prevent disease progression, as evidenced by the reduction of FGF2 protein in the substantia nigra of PD patients. The disconnect between elevated peripheral FGF2 and reduced nigral FGF2 suggests either impaired FGF2 transport to the brain or increased consumption of FGF2 by degenerating neurons. Understanding this compensation may inform therapeutic strategies that augment endogenous FGF signaling.

Signaling Pathway Alterations

In PD, FGF signaling is impaired through multiple mechanisms[@fgf_pd_models]:

The cumulative effect of these impairments is that surviving dopaminergic neurons are unable to receive adequate neurotrophic support, creating a self-reinforcing cycle of progressive degeneration. Restoring FGF signaling represents a rational therapeutic strategy that could interrupt this cycle by providing the molecular signals necessary for neuronal survival and function.

Neuroprotective Mechanisms

Dopaminergic Neuron Protection

FGF2 provides robust neuroprotection in PD models[@fgf_neuroprotection]:

Anti-Inflammatory Effects

FGF signaling modulates neuroinflammation[@fgf_neuroinflammation]:

• Reduces microglial activation
• Promotes anti-inflammatory cytokine production
• Supports astrocyte function

Interaction with PD Proteins

Alpha-Synuclein

FGF signaling interacts with alpha-synuclein pathology through multiple mechanisms that suggest therapeutic potential:

• FGF2 protects against α-synuclein toxicity: Studies in cellular models of alpha-synuclein overexpression demonstrate that FGF2 treatment reduces cytotoxicity and improves neuronal viability. The mechanism involves both direct anti-apoptotic effects and enhancement of protein clearance pathways.
• FGF signaling may reduce aggregation: FGF2 can activate autophagy pathways that promote clearance of alpha-synuclein aggregates. The mTOR-dependent and mTOR-independent autophagy pathways are both engaged by FGF signaling, providing multiple routes to protein clearance.
• Cross-talk with autophagy pathways: FGF2 activates transcription factor EB (TFEB), the master regulator of lysosomal biogenesis, promoting the expression of autophagy and lysosomal genes. This enhancement of cellular clearance capacity may reduce the accumulation of toxic alpha-synuclein species.

LRRK2

LRRK2 mutations affect FGF signaling through kinase-dependent and independent mechanisms:

• G2019S LRRK2 alters FGFR-dependent pathways: The most common pathogenic LRRK2 mutation, G2019S, enhances kinase activity and leads to dysregulated FGFR signaling. LRRK2 can phosphorylate FGFR and downstream signaling molecules, with mutant LRRK2 causing hyperactivation that may contribute to neurotoxicity.
• FGF responses modified in mutant backgrounds: LRRK2 mutant neurons show altered responses to FGF2, with impaired downstream signaling through the MAPK and PI3K/Akt pathways. This suggests that LRRK2 inhibitors may restore FGF responsiveness in patients with LRRK2 mutations.
• Therapeutic implications: Combining LRRK2 inhibition with FGF signaling enhancement may provide synergistic neuroprotection in LRRK2-associated PD.

PINK1/Parkin

FGF signaling intersects with mitophagy through both PINK1/Parkin-dependent and independent mechanisms:

• FGF2 can activate PINK1-independent pathways: FGF2 activates the PI3K/Akt pathway, which can phosphorylate parkin and enhance its E3 ligase activity. This provides an alternative route to mitophagy that does not require PINK1 activation.
• Combined neuroprotective approaches show promise: Strategies that enhance FGF signaling while supporting mitochondrial function through PINK1/parkin-independent pathways may provide robust neuroprotection across diverse genetic causes of PD.

FGF20 and PD

Genetic Associations

FGF20 has been studied in PD through genetic association studies that suggest a role in disease risk[@fgf20_pd]:

• FGF20 polymorphisms associated with PD risk: Initial GWAS identified variants in the FGF20 gene region as associated with increased PD risk in some populations. However, replication has been inconsistent across studies, suggesting population-specific effects or complex gene-environment interactions.
• Expression in substantia nigra: FGF20 shows relatively specific expression in the substantia nigra compared to other brain regions, suggesting that genetic variants affecting FGF20 expression could selectively impact dopaminergic neurons. Single-cell transcriptomic data confirm FGF20 expression in dopaminergic neurons.
• Dopamine neuron-specific effects: The selective expression of FGF20 in dopaminergic neurons makes it an attractive therapeutic target that could provide neuroprotection without affecting other cell types. This specificity may reduce off-target effects compared to more broadly expressed FGF ligands.

Therapeutic Potential

FGF20 represents a PD-specific target with several advantages over other FGF ligands:

• Dopaminergic neuron tropism: The selective expression of FGFR1 in dopaminergic neurons combined with specific FGF20 expression creates a focused neuroprotective pathway that can be therapeutically exploited.
• Neuroprotective effects in models: FGF20 treatment provides neuroprotection in MPTP and 6-OHDA models of PD, with efficacy comparable to or exceeding FGF2 in some studies. The protection extends to both cell body and terminals.
• Lower mitogenic potential than FGF2: Unlike FGF2, which can promote cell proliferation and has been associated with tumorigenic potential in some contexts, FGF20 shows more limited mitogenic activity. This safety advantage may facilitate clinical development.

Therapeutic Implications

FGF-Based Therapies

Recombinant FGF Proteins

• FGF2: Well-characterized neuroprotection
• FGF20: PD-specific potential
• FGF9: Astrocyte support

Gene Therapy Approaches

Viral delivery of FGF genes:

• AAV-FGF2: Shows promise in models
• Cell-type specific promoters
• Regulated expression

Small Molecule FGFR Activators

Challenges:

• FGFR cross-reactivity
• Mitogenic potential (tumor risk)
• BBB penetration

• Allosteric modulators
• Targeted delivery systems
• Combination approaches

Combination Therapies

FGF signaling enhancement may synergize with:

• GDNF family ligands
• Dopamine replacement therapies
• Neuroprotective compounds

Research Directions

Biomarker Development

• FGF levels in CSF as progression markers
• FGFR expression as therapeutic target indicator
• FGF response as treatment biomarker

Clinical Translation

Current focus areas:

Novel Approaches

• Engineered FGF variants with reduced mitogenicity
• Cell-specific targeting
• Induced FGF expression

Conclusion

FGF signaling represents a critical neuroprotective pathway in Parkinson's disease. The specific relevance to dopaminergic neurons and the demonstrated neuroprotective effects in models make this pathway an attractive therapeutic target. However, careful development is required to balance neuroprotection against potential mitogenic effects. Recent advances in BBB-penetrant small molecules and selective FGFR agonists offer promising paths forward.

FGF in Clinical Development

Current Clinical Trials

FGF-based therapies have progressed to clinical testing for neurodegenerative diseases:

| Agent | Target | Phase | Indication |
|-------|-------|-------|------------|
| FGF2 (IV) | FGFR1/2 | Phase I | PD |
| FGF20 (SC) | FGFR1 | Phase I | PD |
| AAV-FGF2 | FGFR1 | Phase I | PD |

Challenges and Solutions

| Challenge | Solution | Status |
|-----------|----------|--------|
| BBB penetration | Modified FGF variants | In development |
| Mitogenic risk | Selective FGFR1 agonists | Preclinical |
| Delivery | AAV-mediated expression | Phase I |
| Dosing | Continuous vs. pulsed | Optimizing |

Advanced Therapeutic Modalities

Gene Therapy Approaches

Viral vector-mediated delivery of FGF genes represents a promising strategy for achieving sustained neurotrophic factor expression in the target brain region:

• AAV-FGF2: Adeno-associated virus serotype 2 (AAV2) carrying the FGF2 gene has been tested in preclinical PD models, showing robust expression in the substantia nigra and striatum with associated neuroprotection. The AAV platform offers advantages including long-term expression, low immunogenicity, and ability to target specific brain regions through stereotactic injection. Current Phase I trials are evaluating safety and expression levels in PD patients.
• AAV-FGF20: The PD-specific FGF20 ligand may provide enhanced targeting of dopaminergic neurons while reducing non-specific effects. Preclinical studies suggest that AAV-FGF20 can protect dopaminergic neurons and improve behavioral outcomes in toxin models.
• Regulated expression: Advanced vector systems incorporating inducible promoters or cell-type specific expression cassettes are being developed to provide better control over FGF expression levels and spatial distribution.

Small Molecule FGFR Activators

The development of small molecule FGFR agonists represents an alternative to protein-based therapies:

• Pan-FGFR agonists: Compounds that activate multiple FGFR isoforms offer broad neurotrophic effects but may increase off-target risks. The challenge lies in achieving sufficient brain penetration while maintaining receptor selectivity.
• FGFR1-selective agonists: Selective targeting of FGFR1 may provide dopaminergic neuron-specific effects with reduced mitogenic concerns in other tissues. Lead optimization efforts have identified FGFR1-selective compounds with favorable pharmacokinetic properties.
• Allosteric modulators: Allosteric FGFR activators may provide more nuanced pathway modulation compared to orthosteric agonists, potentially reducing the risk of excessive signaling.

FGF in Combination Therapies

Synergistic Approaches

FGF signaling enhancement may synergize with other therapeutic modalities:

• With GDNF family: The glial cell line-derived neurotrophic factor (GDNF) family and FGF signaling pathways have complementary effects on dopaminergic neurons. Combination approaches using both neurotrophic factors have shown superior neuroprotection compared to either factor alone in some preclinical studies.
• With dopamine replacement: FGF-mediated neuroprotection may enhance the benefits of L-DOPA therapy by preserving dopaminergic terminals and improving responsiveness to dopamine replacement.
• With disease-modifying agents: Combination with alpha-synuclein aggregation inhibitors, mitochondrial protectants, or anti-inflammatory compounds may provide multi-target disease modification.

Rationale for Combination

The complex pathogenesis of PD involving multiple parallel pathways suggests that combination therapy may be more effective than single-target approaches. FGF signaling interfaces with many of these pathways, providing a central node for therapeutic intervention that can be complemented by agents targeting specific downstream effectors.

See Also

• [EGFR Signaling in Parkinson's Disease](/mechanisms/egfr-parkinsons)
• [PI3K/Akt Signaling in Parkinson's Disease](/mechanisms/pi3k-akt-parkinsons)
• [GDNF Family](/therapeutics/gdnf-family)
• [Neurotrophic Factors](/mechanisms/neurotrophic-factors)
• [Parkinson's Disease Mechanisms](/mechanisms/parkinsons-disease-mechanisms)

References